These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Spencer K; Cowans NJ; Avgidou K; Nicolaides KH Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214 [TBL] [Abstract][Full Text] [Related]
8. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks. Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277 [TBL] [Abstract][Full Text] [Related]
9. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study. von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N; J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837 [TBL] [Abstract][Full Text] [Related]
10. [Noninvasive prenatal test in the first trimester of pregnancy (NT and estimation of beta-hCG and PAPP-A) in the diagnosis of fetal abnormalities in Polish population--comparison of the biochemistry own normal ranges and literature reported data]. Mandryka-Stankewycz S; Perenc M; Dec G; Sieroszewski P Ginekol Pol; 2009 Nov; 80(11):851-5. PubMed ID: 20088400 [TBL] [Abstract][Full Text] [Related]
11. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399 [TBL] [Abstract][Full Text] [Related]
13. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening. Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371 [TBL] [Abstract][Full Text] [Related]
14. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy. Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006 [TBL] [Abstract][Full Text] [Related]
16. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks. Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635 [TBL] [Abstract][Full Text] [Related]
17. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany. Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335 [TBL] [Abstract][Full Text] [Related]
18. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Spencer K; Cicero S; Atzei A; Otigbah C; Nicolaides KH Prenat Diagn; 2005 Oct; 25(10):927-9. PubMed ID: 16088864 [TBL] [Abstract][Full Text] [Related]
19. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21. Sahota DS; Leung TY; Fung TY; Chan LW; Law LW; Lau TK Ultrasound Obstet Gynecol; 2009 Apr; 33(4):387-93. PubMed ID: 19306471 [TBL] [Abstract][Full Text] [Related]